Company intelligence / Profile preview
AiCuris
- Ownership
- Private
- Development stage
- Commercial
01
Overview
AiCuris has a commercial product (Prevymis/letermovir) licensed to Merck for CMV prevention in stem cell transplant patients. Their lead wholly-owned candidate Pritelivir is in Phase III for resistant HSV infections. AIC468 for BK virus is in early clinical development with a first-in-human trial initiated in Q4 2024 and topline data expected in 2025[2][3].
- Therapeutic areas
- Infectious Diseases
- Modalities
- RNA-based therapiesantisense oligonucleotidessmall molecules
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Merck & Co (for Prevymis/letermovir)
Beyond the preview
Go deeper on AiCuris.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AiCuris.